Stock Events

Orexo AB 

$1.5
2
+$0+0% Wednesday 20:00

Statistics

Day High
1.5
Day Low
1.5
52W High
1.95
52W Low
1.12
Volume
6,945
Avg. Volume
0
Mkt Cap
52.37M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24OctExpected
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q2 2024
Next
-1.92
-1.29
-0.67
-0.04
Expected EPS
-0.073796
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORXOF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Pharmaceuticals: Other
Health Technology
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Show more...
CEO
Nikolaj Soerensen
Employees
112
Country
SE
ISIN
SE0000736415

Listings